Midatech raises £10m for gold-nanoparticle delivered insulin and more
This article was originally published in Scrip
Midatech has raised £10m through a new equity round. The investment was led by Ippon Capital, a Geneva-based VC firm, which committed £7.6m. The remainder came from existing investors. The financing is a quick feather in the cap of new CEO Dr Jim Philips, who joined Midatech in September.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.